ter 286 has been researched along with topotecan in 1 studies
| Studies (ter 286) | Trials (ter 286) | Recent Studies (post-2010) (ter 286) | Studies (topotecan) | Trials (topotecan) | Recent Studies (post-2010) (topotecan) |
|---|---|---|---|---|---|
| 21 | 7 | 1 | 2,392 | 626 | 792 |
| Protein | Taxonomy | ter 286 (IC50) | topotecan (IC50) |
|---|---|---|---|
| Cytochrome P450 3A4 | Homo sapiens (human) | 1.5211 | |
| DNA topoisomerase 1 | Homo sapiens (human) | 0.8525 | |
| DNA topoisomerase 2-alpha | Homo sapiens (human) | 0.605 | |
| DNA topoisomerase 2-beta | Homo sapiens (human) | 0.605 | |
| Hypoxia-inducible factor 1-alpha | Homo sapiens (human) | 0.06 | |
| Multidrug and toxin extrusion protein 2 | Homo sapiens (human) | 8.6 | |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | 1.3 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 0.17 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, G; del Campo, J; Finkler, N; Hunter, J; Jones, M; Kavanagh, J; Kaye, S; Lohr, A; Matei, D; Meng, L; Vergote, I; Vermorken, JB | 1 |
1 trial(s) available for ter 286 and topotecan
| Article | Year |
|---|---|
Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Doxorubicin; Drug Resistance, Neoplasm; Female; Glutathione; Humans; Middle Aged; Ovarian Neoplasms; Polyethylene Glycols; Topotecan; Treatment Outcome | 2009 |